---
schema_version: "secwatch.filing_event.v1"
accession: "0001575872-22-000269"
form_type: "8-K"
ticker: "SMNR"
cik: "0001913577"
company_name: "Semnur Pharmaceuticals, Inc."
filed_at: "2022-04-12T23:59:59+00:00"
generated_at: "2026-06-26T08:03:05.450107+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Denali Capital Acquisition Corp. prices $75M IPO, upsized to $82.5M including over-allotment

## Summary
- IPO of 7,500,000 units at $10.00/unit, plus over-allotment of 750,000 units, for total 8,250,000 units.
- Gross proceeds $82.5M from IPO and $5.1M from private placement of 510,000 units to sponsor.
- Trust account funded with $84.15M; proceeds held until business combination or redemption.
- Appoints Huifeng Chang, Jim Mao, Kevin D. Vassily as independent directors; board classified three classes.
- Units (DECAU), Class A shares (DECA), and warrants (DECAW) listed on Nasdaq.

## SEC filing metadata
- accession: 0001575872-22-000269
- form_type: 8-K
- ticker: SMNR
- cik: 0001913577
- company_name: Semnur Pharmaceuticals, Inc.
- filed_at: 2022-04-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/0001575872-22-000269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/deca-20220406.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001575872-22-000269
- JSON: https://secwatch.observer/filing/0001575872-22-000269.json
- Plain text: https://secwatch.observer/filing/0001575872-22-000269.txt

## Key facts
- Executive change
  Huifeng Chang was appointed as Director at Semnur Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/0001575872-22-000269-index.htm
- Executive change
  Jim Mao was appointed as Director at Semnur Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/0001575872-22-000269-index.htm
- Executive change
  Kevin D. Vassily was appointed as Director at Semnur Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective April 6, 2022, in connection with the IPO, Huifeng Chang, Jim Mao and Kevin D. Vassily were appointed directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1913577/000157587222000269/0001575872-22-000269-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.